Nanjing Revamps Medical Trust For Centralized Drug Supply
This article was originally published in PharmAsia News
Nanjing's push for medical trust, which started two years ago, will involve nine third-tier hospitals this May. Under the trust system, health care organizations entrust their pharmacy supply directly to pharmaceutical enterprises to cut expenses. According to statistics from the authorities, drug payment for patients decreased by 10 percent after second-tier hospitals participated in medical trust. Nanjing has established a medical trust center to manage medicine purchasing, drug income and expenses on behalf of nine hospitals. Its specialized central account allows unified billing with drug suppliers, increasing both parties' trust and reducing transaction costs. Analysts say the move represents the government's practical stop-gap approach to address insufficient funding for public hospitals. (Click her for more - Chinese Language)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.